Tempus AI, a precision medicine and AI technology company, saw its stock plunge 5.36% in pre-market trading on Monday. This decline followed the company's announcement of preliminary unaudited financial results for the fourth quarter and full year 2024.
While Tempus reported an expected revenue growth of around 30% year-over-year to approximately $693 million for the full year 2024 and a 35% increase in Q4 2024 revenue to around $200 million, the company acknowledged softness in its contract research organization (CRO) revenues.
Eric Lefkofsky, Tempus' Founder and CEO, stated, "Despite some softness in our CRO revenues, our core businesses gained momentum throughout the year." This admission of weakness in the CRO segment likely contributed to the stock's pre-market decline, despite the company's overall revenue growth and continued improvement in adjusted EBITDA.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.